지놈앤컴퍼니
Financials
Valuation Metrics
지놈앤컴퍼니's Market Cap is ₩1778B. At end of 2025 it was ₩3598B. Ranked #918 of 2,421 in KR market (top 38%), #439 of 1,640 on KOSDAQ (top 27%), #100 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 177.82B KRW | KR#918/2,421 Sec#100/231 |
| Revenue | 24.46B KRW | KR#2,095/2,421 Sec#148/231 |
| Net Income | -43.18B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 122.98B KRW | KR#1,637/2,421 Sec#130/231 |
| Net Assets | 81.29B KRW | KR#1,576/2,421 Sec#127/231 |
| Employees | 102 | KR#1,625/2,421 Sec#128/231 |
| Value | ||
| P/B | 2.19x | KR#1,986/2,421 Sec#149/231 |
| P/S | 7.27x | KR#2,224/2,421 Sec#155/231 |
| FCF Yield | -10.50% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -53.12% | KR#2,284/2,421 Sec#199/231 |
| ROA | -35.11% | KR#2,334/2,421 Sec#205/231 |
| Op. Margin | -119.33% | KR#2,317/2,421 Sec#179/231 |
| Revenue Growth | 1.84% | KR#1,401/2,421 Sec#137/231 |
| Financial Health | ||
| Debt Ratio | 51.28% | KR#977/2,421 Sec#113/231 |
| Total Debt | 21.42B KRW | KR#1,355/2,421 Sec#108/231 |
| FCF | -18.67B KRW | KR#1,878/2,421 Sec#177/231 |
| Cash | 49.91B KRW | KR#738/2,421 Sec#42/231 |
| Current Ratio | 2.31x | KR#751/2,421 Sec#89/231 |
| Performance | ||
| 1Y Return | 24.54% | KR#393/2,421 Sec#27/231 |
| 1M Return | -19.62% | KR#2,297/2,421 Sec#209/231 |
| From 52W High | -66.60% | KR#2,103/2,421 Sec#172/231 |
| 1Y MDD | -70.01% | KR#1,986/2,421 Sec#170/231 |
| Trading | ||
| Volume | 2,090,568 shares | KR#68/2,421 Sec#6/231 |
| Trading Value | 6.65B KRW | KR#314/2,421 Sec#27/231 |
| Foreign Own. | 3.74% | KR#1,105/2,421 Sec#100/231 |
| Per Share | ||
| EPS | -826 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,554 KRW | KR#2,179/2,421 Sec#189/231 |
Company Info
Established in 2015, this global new drug development specialized company went public on KOSDAQ in 2020 and subsequently acquired the management rights of List Labs, a US microbiome CDMO company. Leveraging its Genocle new drug development platform, it researches and develops anticancer drugs and microbiome medicines. The company also operates CDMO, microbiome cosmetics, and health functional food businesses, aiming for integrated pharmaceutical company growth through clinical data-based new drug development and technology transfer commercialization.